Board of Directors

Somu Subramaniam

Managing Partner at New Science Ventures

Somu is the Chairman of our board of directors. Somu is the co-founder and Managing Partner of New Science Ventures. Somu serves on the board of directors of Ralexar Therapeutics, Cambridge Epigenetix, Oxyrane, Resolve Therapeutics, Vascular Therapies and Vaultive. Somu has also served on the board of directors of Dezima Pharma (acquired by Amgen), Ception Therapeutics (acquired by Cephalon), BioVex (acquired by Amgen), and Akarna Therapeutics (acquired by Allergan). Prior to founding New Science Ventures, Somu was a director at McKinsey & Company where he advised leading multinational companies in the pharmaceuticals, medical devices, biotechnology, photonics, software and semiconductor industries. At McKinsey, Somu was leader of the Strategy Practice, the Technology Practice, the Biotechnology Group, and the Healthcare Practice. He also served on the firm’s Investment Committee and led its Equity Portfolio Committee. Somu holds a B.Tech. degree from the Indian Institute of Technology and an M.B.A. from Harvard Business School.

Marco Boorsma, Ph.D.

General Partner at Forbion Capital Partners

Marco is a General Partner at Forbion Capital Partners. He has a background in molecular biology and biotechnology and brings operational and business development experience from both small and large businesses. Before joining Forbion, he was Business Development Director and project manager at DSM Pharmaceutical Products and a scientist at Cytos Biotechnology in Switzerland. Marco also serves on the board of directors of NorthSea Therapeutics, Milestone Pharmaceuticals, RSPR Pharma, Prexton Therapeutics, and Engene, and is an observer to the board of directors of Exosome Diagnostics and Oxyrane. Previously, he served on the board of directors of Dezima Pharma, which was sold to Amgen, and on the board of directors of Akarna Therapeutics, which was sold to Allergan. After obtaining a master’s degree in molecular biology from the University of Groningen, he received his PhD in biotechnology from the ETH Institute for Technology in Zürich, and completed part of his research at the Laboratory of Molecular Biology of the Medical Research Council in Cambridge, UK.

Edward van Wezel

Managing Partner at Biogeneration Ventures

Edward is the Managing Partner of BioGeneration Ventures and currently serves on the board of directors Progentix Orthobiology, Cristal Therapeutics, Synaffix, Staten Biotechnology, and Scenic Biotech. He served on the board of directors of BioCeros (sold in 2011), Noviogendix (acquired by MDxHealth) and was founding investor and supervisory board member of Acerta Pharma (acquired by Astra Zeneca). Edward started his career as process engineer for Chiron Inc. He subsequently worked in product development and corporate licensing at Johnson & Johnson. Since 2000 he expanded his experience as CEO of several life sciences companies in the Netherlands. Edward holds a M.Sc. in chemistry from the University of Utrecht and a M.Sc in Biochemical Engineering from the Delft University of Technology.

Raju Mohan, Ph.D.

Co-Founder, Chief Executive Officer and Director

Raju is a co-founder and has served as our Chief Executive Officer and a member of our board of directors since the company’s inception. Prior to Escalier, Raju founded Akarna Therapeutics, which was acquired by Allergan in 2016 for up to $1.2B and co-founded Ralexar Therapeutics, a dermatology-focused specialty pharmaceutical company. From 2006 to 2011, Raju served as Vice President and head of the San Diego site for Exelixis and Vice President of Chemistry at X-Ceptor Therapeutics (acquired by Exelixis). Raju started his pharmaceutical career at Berlex Biosciences, a subsidiary of Bayer/Schering AG where he held positions of increasing responsibility. Raju is responsible for the discovery of multiple small-molecule candidates that have entered clinical trials. He has published extensively in peer-reviewed journals and is an inventor on 50 issued US patents. Raju received a Ph.D. in Chemistry from the University of Illinois and his Master’s degree from the Indian Institute of Technology.

Norman C. Selby

Norman serves on the board of directors of Infinity Pharmaceuticals, Inc., Merz GmbH & Co. KGaA, Metamark Genetics, Inc., National Parks Conservation Association, Ralph Lauren Center, Ulthera, Inc., Memorial Sloan-Kettering Cancer Center and Central Park Conservancy, Inc. Norman was previously a Senior Advisor with Perseus LLC, Chairman of Windhover Information, Inc., President & Chief Executive Officer of TransForm Pharmaceuticals, Inc., Executive Vice President of Citicorp, Inc., Chief Operating Officer of New York Blood Center, Inc., Director & Senior Partner of McKinsey & Co., Inc., and Chief Executive Officer of Reimbursement Intelligence. He has also served on the board at Ascenta Therapeutics, Inc., Physicians Interactive Holdings LLC, NanoBio Corp., Millennium Pharmaceuticals, Inc., BioForm Medical, Inc., KEW Group, Inc. and Physicians Interactive, Inc. Norman received a B.A. in Architecture from Yale College and an M.B.A. with Distinction from the Harvard Business School.